- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:42 | Sartorius Stedim Biotech Opens New Innovation Center in Massachusetts | 1 | Contract Pharma | ||
| 04.11. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 220 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 26.10. | Sartorius Stedim Biotech Aktie: Was jetzt passieren könnte | gurupress.de | |||
| 20.10. | Sartorius Stedim Biotech Aktie: Quartalszahlen sorgen für Aufschwung | 523 | Börse Global | Sartorius Stedim Biotech, ein führender Anbieter in der biopharmazeutischen Industrie, präsentierte am 17. Oktober 2024 die Ergebnisse des abgelaufenen Quartals. Die Veröffentlichung der Zahlen hatte... ► Artikel lesen | |
| 17.10. | Sartorius Stedim Biotech S.A. reports Q3 results | 23 | Seeking Alpha | ||
| 17.10. | Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 | 448 | Dow Jones News | DJ Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024
Sartorius Stedim Biotech SA / Key word(s): 9 Month figures
Sartorius Stedim Biotech publishes unaudited... ► Artikel lesen | |
| 03.10. | Goldman Sachs starts Stedim shares at "buy", sees more than 20% upside potential | 6 | Investing.com | ||
| 01.10. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 281 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| 15.09. | Sartorius Stedim Biotech Aktie: Halbjahresergebnisse beeinflussen Kursentwicklung | 723 | Börse Global | Die Sartorius Stedim Biotech SA hat am 18. Juli ihre Halbjahresergebnisse für 2024 vorgelegt und gleichzeitig ihre Prognose für das Gesamtjahr angepasst. Der Biotechnologie-Zulieferer verzeichnete im... ► Artikel lesen | |
| 03.09. | Sartorius Stedim shares gets Outperform rating from RBC | 4 | Investing.com | ||
| 03.09. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 233 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 02.08. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 3.155 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 19.07. | Sartorius Stedim Biotech S.A. GAAP EPS of €1.08, revenue of €1.37B | 18 | Seeking Alpha | ||
| 19.07. | Sartorius Stedim Biotech SA: Information on Document Availability | 266 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
19-Jul-2024 / 09:50 CET/CEST... ► Artikel lesen | |
| 18.07. | Sartorius Stedim Biotech SA: Half-year results 2024 - Sales revenue of 1,373 million euros, organic decline of 3.8 percent in constant currencies | 657 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Half Year Results
Half-year results 2024 18-Jul-2024 / 18:30 CET/CEST
Aubagne, France | July 19, 2024
Half-year... ► Artikel lesen | |
| 18.07. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024 | 401 | EQS Group (EN) | Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024 18-Jul-2024 / 18:21 CET/CEST
Dissemination... ► Artikel lesen | |
| 02.07. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 419 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 02.07. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 477 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 04.06. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 487 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 17.05. | Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast | 663 | Dow Jones News | DJ Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech SA / Key word(s): Miscellaneous
Sartorius Stedim Biotech Capital Markets: Links to presentation... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -15,59 % | Evotec Aktie: Optimistische Marktprognosen! | ||
| QIAGEN | 41,045 | +2,05 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| ARCELLX | 90,44 | +3,83 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +5,32 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -1,04 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +8,34 % | Opening Bell: Tech-Aktien am Montag im Plus; Tesla, Palantir, Moderna, Netflix, Nvidia im ... | Nach den jüngsten Kursausschlägen im Zuge des Wahlsiegs von Donald Trump steuern die US-Börsen am Montag auf einen relativ ruhigen Wochenstart zu. Während der Dow Jones Industrial vom Broker IG eine... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,74 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,63 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,38 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
| RELAY THERAPEUTICS | 4,750 | +2,48 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |
Das Unternehmen SARTORIUS STEDIM BIOTECH SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 16,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SARTORIUS STEDIM BIOTECH SA ADR finden Sie auf Wallstreet Online.
